License and Collaboration Agreements (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Aug. 31, 2021	Jan. 07, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Fair value loss on equity investment			$ (3,230,000)	$ 400,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Combioxin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, upfront payment					$ 10,000,000
Collaborative arrangement, rights and obligations, maximum aggregate milestone payments					105,000,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | AOP Orphan Pharmaceuticals GmbH
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, rights and obligations, upfront payment					5,000,000
Collaborative arrangement, rights and obligations, maximum aggregate milestone payments					$ 25,000,000
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Tyme
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Co-promotion agreement, percentage of promotional sales effort responsible for						25.00%
Co-promotion agreement, percentage of net revenue receivable						15.00%
Co-promotion agreement, percentage of net revenue receivable due to collaborator						85.00%
Co-promotion agreement, right to repurchase, amount						$ 200,000,000
Fair value loss on equity investment	$ (700,000)	$ (5,200,000)	$ (3,200,000)	$ 400,000